Compare Crispr Therapeutics AG (CRSP) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Oscar Health Inc — how do they compare? Crispr Therapeutics AG trades at $51.36 (market cap $4.97B), while Oscar Health Inc trades at $30.55 (market cap $9.37B). The key difference: Oscar Health Inc is the larger of the two by market cap, and Oscar Health Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | OSCR | |
|---|---|---|
Market Cap | $4.97B | $9.37B |
Sector | Health | Health |
52-Week High | $76.78 | $32.18 |
52-Week Low | $44.34 | $10.85 |
Enterprise Value | $3.32B | $4.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
OSCR trades at $31.60, up 3.47% today, showing strong momentum near recent highs. The stock exhibits a bullish technical outlook with positive moving average signals and support at $31. Recent Q1 2026 earnings beat expectations with $2.07 EPS versus $1.21 expected, though the company remains unprofitable with a -0.3% net margin. Revenue growth is robust, projected to increase from $11.70B in 2025 to $13.30B in 2026, while operating cash flow strengthens significantly.
The outlook is mixed: strong revenue growth and cash flow improvements support upside potential, but persistent losses and high P/B ratio of 5.63 pose risks. Analyst consensus is cautious with a $22.50 price target below current levels, though technical momentum suggests near-term strength. Key risks include execution on profitability goals and competitive pressures in the health insurance sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
